Table 1.
Demographics and clinical characteristics of cases reported in SECURE-SCD from 20 March 2020 to 23 March 2021
| Variable | Children, 0-18 y | Adults, >18 y |
|---|---|---|
| Total, N (%) | 364 (48.5) | 386 (51.5) |
| Demographics | ||
| Median age (IQR), y | 11 (6-15) | 31 (24-40) |
| Sex, N (%) | ||
| Female | 176 (48.4) | 220 (57.0) |
| Male | 187 (51.4) | 159 (41.2) |
| Race, N (%) | ||
| Black | 330 (90.7) | 324 (83.9) |
| Ethnicity, N (%) | ||
| Hispanic/Latino | 20 (5.5) | 35 (9.1) |
| Genotype, N (%) | ||
| HbSS/HbSβ0 thalassemia | 263 (72.3) | 261 (67.6) |
| HbSC/HbSβ+ thalassemia | 98 (26.9) | 113 (29.3) |
| SCD-related therapy, N (%) | ||
| Hydroxyurea | 203 (55.8) | 191 (49.5) |
| Penicillin | 126 (34.6) | 21 (5.4) |
| Crizanlizumab | 10 (2.7) | 13 (3.4) |
| Voxelotor | 5 (1.4) | 16 (4.1) |
| Glutamine | 10 (2.7) | 14 (3.6) |
| Chronic RBC transfusion | 39 (10.7) | 53 (13.7) |
| COVID-19 severity,* N (%) | ||
| Asymptomatic | 93 (25.5) | 40 (10.4) |
| Mild | 205 (56.3) | 212 (54.9) |
| Moderate | 34 (9.3) | 67 (17.4) |
| Severe | 26 (7.1) | 55 (14.2) |
| Critical | 4 (1.1) | 11 (2.8) |
| COVID-19 outcomes, N (%) | ||
| ED visit | 215 (59.1) | 307 (79.5) |
| Hospitalization | 146 (40.1) | 231 (59.8) |
| ICU admission | 21 (5.8) | 34 (8.8) |
| Ventilator use | 4 (1.1) | 14 (3.6) |
| Death | 1 (0.3) | 18 (4.7) |
RBC, red blood cell.
*Asymptomatic: no clinical signs or symptoms during the positive COVID-19 period. Mild: symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore throat, runny nose, and sneezing or gastrointestinal symptoms or digestive symptoms such as nausea, vomiting, abdominal pain, and diarrhea. Moderate: pneumonia with or without clinical symptoms, no hypoxia. Severe: early respiratory symptoms or gastrointestinal symptoms followed by dyspnea and hypoxia (o2 saturations <92%). Critical: acute respiratory distress syndrome, respiratory failure, encephalopathy, shock, coagulopathy, multiorgan impairment (lung, heart, kidney, brain) that may be life-threatening.